![[feed]](/style/images/feed-icon-14x14.png){kind=icon}
Tools
Tools
Preview |
PDF (Original Article)
- Requires a PDF viewer such as GSview, Xpdf or Adobe Acrobat Reader
789kB |
Preview |
PDF (Supporting Information)
- Requires a PDF viewer such as GSview, Xpdf or Adobe Acrobat Reader
145kB |
| Item Type: | Article |
|---|---|
| Title: | Clinical relevance of circulating MACC1 and S100A4 transcripts for ovarian cancer |
| Creators Name: | Link, T., Kuhlmann, J.D., Kobelt, D., Herrmann, P., Vassileva, Y., Kramer, M., Frank, K., Göckenjan, M., Wimberger, P. and Stein, U. |
| Abstract: | Metastasis-associated in colon cancer 1 (MACC1) and S100 calcium binding protein A4 (S100A4) are prominent inducers of tumor progression and metastasis. For the first time, we systematically tracked circulating serum levels of MACC1 and S100A4 transcripts in the course of surgery and chemotherapy and analyzed their clinical relevance for ovarian cancer. MACC1 and S100A4 transcripts were quantified in a total of 318 serum samples from 79 ovarian cancer patients by RT-qPCR and digital droplet PCR, respectively. MACC1 and S100A4 transcripts were significantly elevated in serum of ovarian cancer patients, compared to healthy controls (P=0.024; P<0.001). At primary diagnosis, high levels of MACC1 or S100A4 correlated with advanced FIGO-stage (P=0.042; P=0.008), predicted suboptimal debulking surgery and indicated shorter progression-free survival (PFS; P=0.003; P=0.001) and overall survival (OS; P<0.001; P=0.002). This is the first study in ovarian cancer to propose circulating MACC1 and S100A4 transcripts as potential liquid biopsy markers. |
| Keywords: | Ovarian Cancer, MACC1, S100A4, Blood-Based Biomarker, Prognosis, Survival |
| Source: | Molecular Oncology |
| ISSN: | 1574-7891 |
| Publisher: | Wiley |
| Volume: | 13 |
| Number: | 5 |
| Page Range: | 1268-1279 |
| Date: | May 2019 |
| Official Publication: | https://doi.org/10.1002/1878-0261.12484 |
| PubMed: | View item in PubMed |
Repository Staff Only: item control page
